Search results for "placebo-controlled"

showing 10 items of 93 documents

Adjuvante Ganzkörper- akupunktur bei Depression

1998

In order to examine the efficacy of whole body acupuncture additionally applied to drug treatment in depression, a single-blind placebo-controlled study with 70 inpatients administered to three different treatment groups has been carried out. All patients were pharmacologically treated with the tetracyclic antidepressant mianserin. The verum group (n = 22) received acupuncture at specific points considered to be effective in the treatment of depression. The placebo group (n = 24) was treated with acupuncture at non-specific locations and the control group (n = 24) received only pharmacological treatment. Acupuncture was applied three times a week over a period of four weeks. Psychopathology…

business.industrymedicine.medical_treatmentPlacebo-controlled studyGeneral MedicineMianserinPlaceboTetracyclic antidepressantPsychiatry and Mental healthNeurologyRating scaleAnesthesiaAcupuncturemedicineNeurology (clinical)businessDepression (differential diagnoses)medicine.drugPsychopathologyDer Nervenarzt
researchProduct

Effects of soluble milk protein or casein supplementation on muscle fatigue following resistance training program: a randomized, double-blind, and pl…

2014

International audience; Background: The effects of protein supplementation on muscle thickness, strength and fatigue seem largely dependent on its composition. The current study compared the effects of soluble milk protein, micellar casein, and a placebo on strength and fatigue during and after a resistance training program. Methods: Sixty-eight physically active men participated in this randomized controlled trial and underwent 10 weeks of lower-body resistance training. Participants were randomly assigned to the Placebo (PLA), Soluble Milk Protein (SMP, with fast digestion rate) or Micellar Casein (MC, with slow digestion rate) group. During the 10-week training period, participants were …

medicine.medical_specialty030309 nutrition & dieteticsPlacebo-controlled studyEXERCISE[SDV.GEN] Life Sciences [q-bio]/GeneticsClinical nutritionBioinformaticsPlaceboCHAIN AMINO-ACIDSlaw.inventionEndurance03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicineCaseinCARBOHYDRATEmedicine[SDV.GEN]Life Sciences [q-bio]/Genetics0303 health sciencesNutrition and DieteticsMilk proteinMuscle fatigueATTENUATES FATIGUEbusiness.industry030229 sport sciencesN-ACETYLCYSTEINEPERFORMANCEBranched-chain amino acidsHYPERTROPHYEndocrinologyMuscle powerADAPTATIONSMuscle thicknessSKELETAL-MUSCLE[ SCCO ] Cognitive scienceDigestionbusiness[ SDV.GEN ] Life Sciences [q-bio]/GeneticsResearch ArticleFood ScienceINGESTION
researchProduct

Granulocyte–Macrophage Colony-Stimulating Factor in the Therapy of Adults with De Novo Acute Myeloblastic Leukemia: An Update of a Double-Blind Rando…

1997

We investigated whether granulocytemacrophage colony-stimulating factor (GMCSF) given concomitantly with chemotherapy (CT) improves the outcome of adults with de novo acute myeloblastic leukemia (AML) by increasing the efficacy of CT and reducing infections. CT included cytarabine (ara-C) daunorubicin, and etoposide (DAV) for induction and early consolidation therapy and one cycle with high-dose (patients aged ≤50 years) or intermediate-dose ara-C (patients aged >50 years) /daunorubicin for late consolidation therapy. Eighty patients were randomized after DAV 1 to receive either GM-CSF (Escherichia coli, 250 µg/m2 per day, s.c.) or placebo starting 48 h prior to DAV II and the subsequent co…

medicine.medical_specialtyChemotherapybusiness.industrymedicine.medical_treatmentPlacebo-controlled studyPlaceboGastroenterologyExact testMedian follow-upInternal medicineCytarabinemedicineAbsolute neutrophil countPhysical therapybusinessEtoposidemedicine.drug
researchProduct

Multicentre randomized placebo-controlled trial of ursodeoxycholic acid with or without colchicine in symptomatic primary biliary cirrhosis

2000

Aim: To establish the efficacy of combination therapy with ursodeoxycholic acid (UDCA) and colchicine in patients with symptomatic primary biliary cirrhosis (PBC), defined by the presence of liver cirrhosis, pruritus or bilirubin exceeding 2 mg/mL. Methods: A total of 90 patients were randomly assigned to ursodeoxycholic acid 500 mg/daily plus placebo (UDCA group, n=44), or ursodeoxycholic acid at the same dosage plus colchicine, 1 mg/daily (UDCA/C group, n=46). The two groups were comparable for age, sex, stage of disease, severity of pruritus, bilirubin, and Mayo score. All patients underwent clinical, ultrasonographic, and biochemical examinations at entry and then every 6 months up to 3…

medicine.medical_specialtyCirrhosisHepatologymedicine.diagnostic_testbusiness.industryBiliary cirrhosisGastroenterologyPlacebo-controlled studymedicine.diseasePlaceboGastroenterologyUrsodeoxycholic acidPrimary biliary cirrhosisCholestasisLiver biopsyInternal medicinemedicinePharmacology (medical)businessmedicine.drugAlimentary Pharmacology & Therapeutics
researchProduct

Prospective Comparison on Cardiac Iron and Liver Iron by MR In Thalassemia Major Patients Treated with Combination Deferipron–Desferrioxamine Versus …

2010

Abstract Abstract 5164 Introduction: Using T2* MR a randomised placebo controlled study from Sardinia demonstrated combination therapy with deferiprone and desferrioxamine (DFP+DFO) significantly more effective than DFO in improving myocardial iron. One non-randomised study from Sardinia and one observational study from Greece seem to confirm for DFP+DFO therapy the most rapid clearance of cardiac iron. No data are available in literature about prospective comparisons on cardiac iron and function and liver iron in TM patients treated with DFP+DFO versus DFP and DFO in monotherapy. The aim of this multi-centre study was to assess prospectively in a large clinical setting the efficacy of the …

medicine.medical_specialtyCombination therapybusiness.industryThalassemiaImmunologyUrologyPlacebo-controlled studyCell BiologyHematologymedicine.diseaseBiochemistryDeferipronSurgeryBiventricular functionchemistry.chemical_compoundchemistrymedicineCardiac ironLiver ironDeferipronebusiness
researchProduct

High- versus low-dose ACE inhibition in chronic heart failure

1998

Abstract Objectives. To determine dose-related clinical and neurohumoral effects of angiotensin-converting enzyme (ACE) inhibitors in patients with chronic heart failure (CHF), we conducted a double-blind, placebo-controlled, randomized study of three doses (2.5 mg, 5 mg and 10 mg) of the long-acting ACE inhibitor imidapril. Background. The ACE inhibitors have become a cornerstone in the treatment of CHF, but whether high doses are more effective than low doses has not been fully elucidated, nor have the mechanisms involved in such a dose-related effect. Methods. In a parallel group comparison, the effects of three doses of imidapril were examined. We studied 244 patients with mild to moder…

medicine.medical_specialtyDigoxinbiologybusiness.industryPlacebo-controlled studyAngiotensin-converting enzymemedicine.diseasePlaceboEndocrinologyImidaprilInternal medicineHeart failureACE inhibitorbiology.proteinCardiologyMedicineEnalaprilCardiology and Cardiovascular Medicinebusinessmedicine.drugJournal of the American College of Cardiology
researchProduct

Traumatic brain injury: integrated approaches to improve prevention, clinical care, and research

2017

Executive summary A concerted effort to tackle the global health problem posed by traumatic brain injury (TBI) is long overdue. TBI is a public health challenge of vast, but insufficiently recognised, proportions. Worldwide, more than 50 million people have a TBI each year, and it is estimated that about half the world’s population will have one or more TBIs over their lifetime. TBI is the leading cause of mortality in young adults and a major cause of death and disability across all ages in all countries, with a disproportionate burden of disability and death occurring in low-income and middle-income countries (LMICs). It has been estimated that TBI costs the global economy approximately $…

medicine.medical_specialtyEVIDENCE-BASED MEDICINETreatment outcomePoison controlOther Research Radboud Institute for Molecular Life Sciences [Radboudumc 0]EMERGENCY-DEPARTMENT VISITSReviewPLACEBO-CONTROLLED TRIALMiddle income countryHealthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18]03 medical and health sciences0302 clinical medicineIntensive careBrain Injuries TraumaticJournal Articlemedicinetraumatic barin injuryHumans030212 general & internal medicineClinical careNeurologic diseasePsychiatryDIAGNOSTIC MANAGEMENT STRATEGIESbusiness.industryRANDOMIZED CONTROLLED-TRIALACUTE SUBDURAL-HEMATOMASEVERE HEAD-INJURYROAD TRAFFIC INJURIESbrain injuryHospital care3. Good healthReconstructive and regenerative medicine Radboud Institute for Health Sciences [Radboudumc 10]Brain InjuriesHealth care costPATIENT-REPORTED OUTCOMESHuman medicineNeurology (clinical)businessHumanities030217 neurology & neurosurgeryGLASGOW COMA SCALE
researchProduct

2021

ObjectiveTo assess the safety and efficacy of epigallocatechin-3-gallate (EGCG) add-on to glatiramer acetate (GA) in patients with relapsing-remitting multiple sclerosis (RRMS).MethodsWe enrolled patients with RRMS (aged 18–60 years, Expanded Disability Status Scale [EDSS] score 0–6.5), receiving stable GA treatment in a multicenter, prospective, double-blind, phase II, randomized controlled trial. Participants received up to 800 mg oral EGCG daily over a period of 18 months. The primary outcome was the proportion of patients without new hyperintense lesions on T2-weighted (T2w) brain MRI within 18 months. Secondary end points included additional MRI and clinical parameters. Immunologic eff…

medicine.medical_specialtyExpanded Disability Status Scalebusiness.industryMultiple sclerosisPlacebo-controlled studymedicine.diseasePlaceboGastroenterologylaw.inventionClinical trial03 medical and health sciences0302 clinical medicineNeurologyRandomized controlled triallawInternal medicinemedicine030212 general & internal medicineNeurology (clinical)Glatiramer acetateAdverse effectbusiness030217 neurology & neurosurgerymedicine.drugNeurology: Neuroimmunology & Neuroinflammation
researchProduct

OARSI/OMERACT Initiative to Define States of Severity and Indication for Joint Replacement in Hip and Knee Osteoarthritis. An OMERACT 10 Special Inte…

2011

Objective.To define pain and physical function cutpoints that would, coupled with structural severity, define a surrogate measure of “need for joint replacement surgery,” for use as an outcome measure for potential structure-modifying interventions for osteoarthritis (OA).Methods.New scores were developed for pain and physical function in knee and hip OA. A cross-sectional international study in 1909 patients was conducted to define data-driven cutpoints corresponding to the orthopedic surgeons’ indication for joint replacement. A post hoc analysis of 8 randomized clinical trials (1379 patients) evaluated the prevalence and validity of cutpoints, among patients with symptomatic hip/knee OA.…

medicine.medical_specialtyJoint replacementmedicine.medical_treatmentImmunologyPROGRESSIONOsteoarthritisPLACEBO-CONTROLLED TRIAL2-YEARArticlelaw.inventionRADIOGRAPHIC FEATURES03 medical and health sciencesDOUBLE-BLIND0302 clinical medicinePhysical medicine and rehabilitationRheumatologyRandomized controlled triallawSeverity of illnessPost-hoc analysismedicinePHYSICAL-FUNCTIONImmunology and Allergy030212 general & internal medicine030203 arthritis & rheumatologyHip surgery3-YEARbusiness.industry[SCCO.NEUR]Cognitive science/Neuroscience[SCCO.NEUR] Cognitive science/NeurosciencePAINASSOCIATIONmedicine.diseaseArthroplasty3. Good healthGLUCOSAMINE SULFATEOSTEOARTHRITIS SEVERITY PAIN FUNCTION STRUCTURE OUTCOME MEASURE placebo-controlled trial double-blind radiographic features glucosamine sulfate physical-function progression pain association 3-year 2-yearOrthopedic surgeryPhysical therapybusiness
researchProduct

Effects of topical treatment with the raft modulator miltefosine and clobetasol in cutaneous mastocytosis: a randomized, double-blind, placebo-contro…

2009

Background Mastocytosis is characterized by the accumulation and activation of mast cells in different organs, most commonly the skin. Miltefosine, a raft modulator, has recently been shown to inhibit the activation of mast cells and to reduce mast cell-driven skin inflammatory responses. Objectives To study the safety and efficacy of topical miltefosine treatment of skin lesions in patients with mastocytosis. Methods Thirty-nine adult patients with mastocytosis with skin involvement were treated in a double-blind, placebo-controlled, parallel trial with topical miltefosine and clobetasol for 2 weeks. Treatment areas were analysed for changes in skin lesions and symptoms following mechanica…

medicine.medical_specialtyMiltefosinebusiness.industryCutaneous MastocytosisProvocation testPlacebo-controlled studyDermatologyMast cellDermatologylaw.inventionmedicine.anatomical_structurePharmacotherapyRandomized controlled trialDermislawMedicinebusinessmedicine.drugBritish Journal of Dermatology
researchProduct